(242 days)
None
No
The description focuses on hardware components (dosimeter, reader, wand, base station) and software for data storage and reporting. There is no mention of algorithms, learning, or adaptive capabilities that would indicate AI/ML.
No.
The DVS System is designed to measure and verify radiation dose, acting as an adjunct to treatment planning for validation of prescribed doses, rather than directly treating a condition.
Yes
The device is used to verify treatment planning and the radiation dose received by tissues, acting as an "adjunct to treatment planning" to validate the prescribed dose. This ongoing verification of the actual dose received, as opposed to the planned dose, serves a diagnostic function in assessing the effectiveness and accuracy of the radiation therapy.
No
The device description clearly outlines multiple hardware components: the DVS Implantable Dosimeter, the DVS Insertion Tool, and the DVS Reader System (Wand and Base Station). While it includes software (Plan and Review Software and Dosimetry Database), it is part of a larger system that relies on physical hardware for data acquisition and interaction.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used to examine these samples outside of the body.
- DVS Function: The DVS (Dose Verification System) is designed to measure radiation dose in vivo (within the living body) using an implantable dosimeter. It directly measures the radiation received by tissues and organs during radiation therapy.
- Lack of Sample Analysis: The system does not analyze biological samples taken from the patient. It measures a physical parameter (radiation dose) directly within the body.
Therefore, the DVS falls outside the scope of an In Vitro Diagnostic device. It is a device used for monitoring and verifying radiation dose during a medical treatment procedure.
N/A
Intended Use / Indications for Use
The DVS (Dose Verification System) is intended for use in radiation therapy to verify treatment planning and radiation dose to tissue and organs in or near the irradiated areas of a patient.
The DVS system is specifically indicated for breast cancer to measure photon beam therapy and as an adjunct to treatment planning to permit measurement of the in vivo radiation dose received at the tumor periphery, tumor bed and/or surrounding normal tissues for validation of the prescribed dose.
Product codes
LHN, NZT
Device Description
The DVS, Dose Verification System consists of four sub-systems: the DVS Implantable Dosimeter for measuring radiation dose in vivo, the DVS Insertion Tool for implanting the dosimeter during percutaneous procedures, the DVS Reader System (Wand and Base Station) for powering the dosimeter and providing a user interface when taking dose measurements, and the DVS Data System (Plan and Review Software and Dosimetery Database) for storing and reporting patient data and for storing dosimeter information. The dosimeters use a MOSFET, Metal Oxide Semiconductor Field Effect Transistor as a sensing mechanism. The dosimeter is factory calibrated and powered by the Reader Wand utilizing electromagnetic energy. The dosimeter contains a transmitter, to transmit threshold voltage readings to the reader. It is radioopague and thus registers on computed tomography scans as a point of interest whereby a point dose may be determined. Patients are implanted prior to radiotherapy. Information on the patient's therapy, dose planning, point dose at the dosimeter, dosimeter serial number and calibration files are entered into the Plan and Review software and stored in the Dosimetry Database. At each therapy fraction the dosimeter is read pre- and post-therapy using the Reader Wand and Base Station. This translates into a daily fractional dose. The patient's daily and cumulative dose may be reviewed via the Plan and Review software. Because the Plan and Review software and Dosimetry Database are designed to be stored on a server, up to 25 users may be logged into the system at any one time. Reports on the patient's daily and cumulative dose history may be printed using the Plan and Review software.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
computed tomography
Anatomical Site
tissue and organs in or near the irradiated areas of a patient, breast cancer, tumor periphery, tumor bed and/or surrounding normal tissues
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance studies, pre-clinical studies, and clinical studies contained within the 510(k) are described in sufficient detail to demonstrate that the DVS is safe and effective and that the technological differences described here do not present any new issues of safety and effectiveness compared to other currently marketed devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K932598, K013279, K010472, K032725, K041557, K040687, K925416
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of 21 CFR Part 807.87 (h).
Submitter:
Koszll8
Sicel Technologies, Inc. 3800 Gateway Centre Blvd. Suite 308 Morrisville, NC 27560
Contact: Tammy B. Carrea, Director Regulatory Affairs Phone: (919) 465-2236 ext. 225 Fax:
Prepared: August 3, 2005
| Common or Usual
| Name: | Patient Radiation Dosimeter |
|---|---|
| Proprietary Name: | DVS, Dose Verification System |
| Classification Name: | Accelerator, Linear, Medical |
| Manufactured By: | Sicel Technologies, Inc. |
| 3800 Gateway Centre Blvd. | |
| Suite 308 | |
| Morrisville, NC 27560 |
Phone: (919) 465-2236
Fax: (919) 465-0153 |
1
Predicate Device(s):
Thomson Nielsen K932598, K013279, K010472, K032725, and K041557 TN-RD-50, MOSFET Autosense Wireless Dosimetry System, mobileMOSFET Dosimetry System
Sicel Technologies, Inc. K040687 OneDose Patient Dosimetry System
Symbiosis K925416 Bone Biopsy Needle
Device Description:
The DVS, Dose Verification System consists of four sub-systems: the DVS Implantable Dosimeter for measuring radiation dose in vivo, the DVS Insertion Tool for implanting the dosimeter during percutaneous procedures, the DVS Reader System (Wand and Base Station) for powering the dosimeter and providing a user interface when taking dose measurements, and the DVS Data System (Plan and Review Software and Dosimetery Database) for storing and reporting patient data and for storing dosimeter information. The dosimeters use a MOSFET, Metal Oxide Semiconductor Field Effect Transistor as a sensing mechanism. The dosimeter is factory calibrated and powered by the Reader Wand utilizing electromagnetic energy. The dosimeter contains a transmitter, to transmit threshold voltage readings to the reader. It is radioopague and thus registers on computed tomography scans as a point of interest whereby a point dose may be determined. Patients are implanted prior to radiotherapy. Information on the patient's therapy, dose planning, point dose at the dosimeter, dosimeter serial number and calibration files are entered into the Plan and Review software and stored in the Dosimetry Database. At each therapy fraction the dosimeter is read pre- and post-therapy using the Reader Wand and Base Station. This translates into a daily fractional dose. The patient's daily and cumulative dose may be reviewed via the Plan and Review software. Because the Plan and Review software and Dosimetry Database are designed to be stored on a server, up to 25 users may be logged into the system at any one time. Reports on the patient's daily and cumulative dose history may be printed using the Plan and Review software.
2
Indication for Use:
$$
\mathbb{K} \lhd \mathcal{K} \lhd \mathcal{K}
$$
The DVS (Dose Verification System) is intended for use in radiation therapy to verify treatment planning and radiation dose to tissue and organs in or near the irradiated areas of a patient.
The DVS system is specifically indicated for breast cancer to measure photon beam therapy and as an adjunct to treatment planning to permit measurement of the in vivo radiation dose received at the tumor periphery, tumor bed and/or surrounding normal tissues for validation of the prescribed dose.
Comparison with Predicate Device:
The intended use of the SICEL DVS is identical to predicates such as the Thomson Nielsen Dose Verification System (K932598, K013279, K010472, K032725, and K041557) to verify that the radiation dose delivered corresponds to the dose plan.
The indications for use of the SICEL DVS also are substantially the same as the indications for use of the Thomson Nielsen device. Although the SICEL DVS is indicated for use to measure dose at the tumor's periphery, tumor bed, or in the surrounding tissue, while the Thomson Nielsen device is indicated for use to measure dose delivered "to the patient," the Thomson Nielsen device may be used for intracavity placement and, in conjunction with associated software, is able to calculate the dose delivered within the patient's body as a midline dose.
The technological features of the SICEL DVS are substantially the same as the predicates, including the use of MOSFET technology, as in the Thomson Nielsen device and the OneDose. The calibration, dose range, energy sources measured, and dose management software also are very similar to the Thomson Nielsen device.
There are three technological differences: the DVS is implantable, and because it is implantable materials and duration of use are different, and the DVS is telemetric and not tethered. Several other oncology devices currently marketed including brachytherapy seeds and radiographic marks are similar in size, position of implantation in vivo, use similar implantation techniques and tools, and are designed for permanent implantation. In addition other devices such as the Given Imaging Capsule, Cortemp Ingestible Capsule, and the Verichip Microtransponder, transmit data telemetrically to a reader system. The Given Imaging Capsule, the Jones Tube, and the Verichip Microtransponder also utilize similar materials contained within the DVS implantable dosimeter and are a similar size. Performance studies, pre-clinical studies, and clinical studies contained within the 510(k) are described in sufficient detail to demonstrate that the DVS is safe and effective and that the technological differences described here do not present any new issues of safety and effectiveness compared to
3
other currently marketed devices.
Kusall P
The DVS, Dose Verification System is calibrated at the factory using the same method as the Thomson Nielsen for evaluating radiation units/volts except that the DVS, Dose Verification System is calibrated under controlled conditions at the factory and the Thomson Nielsen device must be calibrated by the user. Also the OneDose Dosimeter is likewise factory calibrated and the factory calibration is verified by an external ADCL lab in the same manner as the OneDose. The factory calibration procedure is described in sufficient detail within the 510(k) to demonstrate the methods used to assure calibration and the data contained with the performance data section demonstrates that calibrated devices perform within the stated performance specifications of the labeling.
The DVS, Dose Verification System is a sterile, single use dosimeter.
Thus, the DVS, Dose Verification System is substantially equivalent to the Thomson Nielsen Patient Dose Verification System (K932598, K013279, K010472, K032725, and K041557), OneDose Patient Dosimetry System (K040687), and the Symbiosis Bone Biopsy Needle (K925416).
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular pattern around the eagle. The logo is black and white.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
OCT 1 0 2006
Ms. Tammy B. Carrea Director, Regulatory Affairs Sicel Technologies, Inc. 3800 Gateway Centre Boulevard Suite 308 MORRISVILLE NC 27560
Re: K052118
Trade Name: DVS, Dose Verification System Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: LHN and NZT Dated: December 30, 2005 Received: January 3, 2006
Dear Ms. Carrea:
This letter corrects our substantially equivalent letter of April 3, 2006.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
Image /page/4/Picture/13 description: The image is a circular logo with the text "1906 - 2006" at the top. Below the text is the acronym "FDA" in large, bold letters. Underneath "FDA" is the word "Centennial" in a cursive font. There are three stars below the word "Centennial". The text around the circle reads "U.S. FOOD & DRUG ADMINISTRATION PROTECTING AMERICA'S HEALTH IN YOUR SCHOOLS & PUBLIC".
Protecting and Promoting Public Health
5
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address
http://www.fda.gov/cdrh/dsma/dsmamain.html
m
Sincerely yours,
David A. Seegram
Nancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Indications for Use Statement
510(k) Number (if known):
Kos2118
Device Name: DVS, Dose Verification System
Indications for Use:
Intended Use
The DVS (Dose Verification System) is intended for use in radiation therapy to verify treatment planning and radiation dose to tissue and organs in or near the irradiated areas of a patient.
Indications for Use
The DVS system is specifically indicated for breast cancer to measure photon beam therapy and as an adjunct to treatment planning to permit measurement of the in vivo radiation dose received at the tumor periphery, tumor bed and/or surrounding normal tissues for validation of the prescribed dose.
(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 C.F.R. 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)
(Division Sign-Off) Division of Reproductive. Abdominal, and Radiological Devices 510(k) Number
Sicel Technologies, Inc. DVS Dose Verification System 510(k)
220